Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
International Journal of Chronic Obstructive Pulmonary Disease|May 12, 2021
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important ImprovementClaus F Vogelmeier, Ian P Naya, François Maltais, et al.
Therapeutic Advances in Respiratory Disease|May 29, 2020
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trialEdward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX TrialLeif Bjermer, Isabelle H Boucot, François Maltais, et al.
Chronic Respiratory Disease|October 6, 2023
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?Edward M Kerwin, Paul W Jones, Leif H Bjermer, et al.
Respiratory Medicine|July 8, 2022
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPDFrançois Maltais, Claus F Vogelmeier, Edward M Kerwin, et al.
Therapeutic Advances in Respiratory Disease|November 10, 2020
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trialClaus F Vogelmeier, Edward M Kerwin, Leif H Bjermer, et al.
Pulmonary Therapy|March 6, 2024
Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT StudyBhumika Aggarwal, Paul Jones, Alejandro Casas, et al.
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|November 1, 2019
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialFrançois Maltais, Leif Bjermer, Edward M Kerwin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
Pageof 5